Report on challenges with respect to the administration and staffing of amyotrophic lateral sclerosis clinical trials

Not later than 90 days after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Director of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, shall submit to Congress and publish on the internet website of the agency a report that identifies— (1) any challenges with respect to the administration and staffing of clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis; (2) actions that the Director of the National Institute of Neurological Disorders and Stroke can take to address such challenges; and (3) any legislative recommendations (including requests for appropriations) to further improve the administration of such clinical trials.